Stent delivery under direct visualization

Information

  • Patent Grant
  • 10278849
  • Patent Number
    10,278,849
  • Date Filed
    Thursday, September 18, 2014
    10 years ago
  • Date Issued
    Tuesday, May 7, 2019
    5 years ago
Abstract
A tissue manipulation system comprises a reconfigurable hood structure with a distal end. The hood structure has a membrane extending across the hood structure distal end. The membrane includes an aperture with an aperture diameter smaller than an outer lip diameter of the hood structure in the expanded deployed configuration. The system also includes a fluid lumen in communication with the open area and an inflatable balloon member translatable through the aperture in the membrane and distal to the open area. The system also comprises an expandable stent positioned upon the balloon member. The stent has an unexpanded configuration sized to pass through the aperture in the membrane.
Description
FIELD OF THE INVENTION

The present invention relates generally to stent delivery systems which may be used to place one or more stents along a lesion. More particularly, the present invention relates to methods and apparatus for the delivery of one or more stents along a lesion, such as an ostial lesion or along a stenosed region (e.g., caused by atherosclerotic plaque) at various locations, for instance along the coronary vessels, renal arteries, etc., while directly visualizing the tissue region.


BACKGROUND OF THE INVENTION

Conventional devices for visualizing interior regions of a body lumen are known. For example, ultrasound devices have been used to produce images from within a body in vivo. Ultrasound has been used both with and without contrast agents, which typically enhance ultrasound-derived images.


Other conventional methods have utilized catheters or probes having position sensors deployed within the body lumen, such as the interior of a cardiac chamber. These types of positional sensors are typically used to determine the movement of a cardiac tissue surface or the electrical activity within the cardiac tissue. When a sufficient number of points have been sampled by the sensors, a “map” of the cardiac tissue may be generated.


Another conventional device utilizes an inflatable balloon which is typically introduced intravascularly in a deflated state and then inflated against the tissue region to be examined. Imaging is typically accomplished by an optical fiber or other apparatus such as electronic chips for viewing the tissue through the membrane(s) of the inflated balloon. Moreover, the balloon must generally be inflated for imaging. Other conventional balloons utilize a cavity or depression formed at a distal end of the inflated balloon. This cavity or depression is pressed against the tissue to be examined and is flushed with a clear fluid to provide a clear pathway through the blood.


However, such imaging balloons have many inherent disadvantages. For instance, such balloons generally require that the balloon be inflated to a relatively large size which may undesirably displace surrounding tissue and interfere with fine positioning of the imaging system against the tissue. Moreover, the working area created by such inflatable balloons are generally cramped and limited in size. Furthermore, inflated balloons may be susceptible to pressure changes in the surrounding fluid. For example, if the environment surrounding the inflated balloon undergoes pressure changes, e.g., during systolic and diastolic pressure cycles in a beating heart, the constant pressure change may affect the inflated balloon volume and its positioning to produce unsteady or undesirable conditions for optimal tissue imaging. Additionally, imaging balloons are subject to producing poor or blurred tissue images if the balloon is not firmly pressed against the tissue surface because of intervening blood between the balloon and tissue.


Accordingly, these types of imaging modalities are generally unable to provide desirable images useful for sufficient diagnosis and therapy of the endoluminal structure, due in part to factors such as dynamic forces generated by the natural movement of the heart. Moreover, anatomic structures within the body can occlude or obstruct the image acquisition process. Also, the presence and movement of opaque bodily fluids such as blood generally make in vivo imaging of tissue regions within the heart difficult.


Other external imaging modalities are also conventionally utilized. For example, computed tomography (CT) and magnetic resonance imaging (MRI) are typical modalities which are widely used to obtain images of body lumens such as the interior chambers of the heart. However, such imaging modalities fail to provide real-time imaging for intra-operative therapeutic procedures. Fluoroscopic imaging, for instance, is widely used to identify anatomic landmarks within the heart and other regions of the body. However, fluoroscopy fails to provide an accurate image of the tissue quality or surface and also fails to provide for instrumentation for performing tissue manipulation or other therapeutic procedures upon the visualized tissue regions. In addition, fluoroscopy provides a shadow of the intervening tissue onto a plate or sensor when it may be desirable to view the intraluminal surface of the tissue to diagnose pathologies or to perform some form of therapy on it.


In one particular treatment, intravascular stents are commonly used to maintain the patency of a vascular lumen. Conventional stent delivery systems typically employ intravascular ultrasound (IVUS) for selecting the appropriate stent and placing it at the site of lesions, e.g., ostial lesions. However, such assessment and placement methods are not accurate. For instance, the treatment site may be located in the right coronary artery immediately adjacent to the ostium in the aortic wall. In such instances, it is often difficult to accurately position an intravascular stem such that the stent does not extend too far proximal to the ostium. Accuracy in placing the stent at the desired location is typically affected by, e.g., limited visualization of the ostium, angulations of the aorto-coronary segment, and the difficulties in the placement of the guiding catheter.


Accurate positioning of the stent along the ostial lesion is particularly desirable because (a) if the stent is placed too proximal to the ostium, the protrusion of the stent into the aortic lumen can cause thrombus or other complications; and (b) if the stent is placed too distal to the ostium, the stent may not be able to subdue the ostial lesion completely thereby resulting in low success rate and high incidence of re-stenosis or recurrence of arterial blockage.


Thus, methods and/or apparatus which are able to allow for accurate positioning of the stent relative to the ostial lesion is highly desirable.


SUMMARY OF THE INVENTION

A tissue imaging and manipulation apparatus that may be utilized for procedures within a body lumen, such as the heart, in which visualization of the surrounding tissue is made difficult, if not impossible, by medium contained within the lumen such as blood, is described below. Generally, such a tissue imaging and manipulation apparatus comprises an optional delivery catheter or sheath through which a deployment catheter and imaging hood may be advanced for placement against or adjacent to the tissue to be imaged.


The deployment catheter may define a fluid delivery lumen therethrough as well as an imaging lumen within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, the imaging hood may be expanded into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field is defined by the imaging hood. The open area is the area within which the tissue region of interest may be imaged. The imaging hood may also define an atraumatic contact lip or edge for placement or abutment against the tissue region of interest. Moreover, the distal end of the deployment catheter or separate manipulatable catheters may be articulated through various controlling mechanisms such as push-pull wires manually or via computer control


The deployment catheter may also be stabilized relative to the tissue surface through various methods. For instance, inflatable stabilizing balloons positioned along a length of the catheter may be utilized, or tissue engagement anchors may be passed through or along the deployment catheter for temporary engagement of the underlying tissue.


In operation, after the imaging hood has been deployed, fluid may be pumped at a positive pressure through the fluid delivery lumen until the fluid fills the open area completely and displaces any blood from within the open area. The fluid may comprise any biocompatible fluid, e.g., saline, water, plasma, Fluorinert™, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. The fluid may be pumped continuously or intermittently to allow for image capture by an optional processor which may be in communication with the assembly.


In an exemplary variation for imaging tissue surfaces within a heart chamber containing blood, the tissue imaging and treatment system may generally comprise a catheter body having a lumen defined therethrough, a visualization element disposed adjacent the catheter body, the visualization element having a field of view, a transparent fluid source in fluid communication with the lumen, and a barrier or membrane extendable from the catheter body to localize, between the visualization element and the field of view, displacement of blood by transparent fluid that flows from the lumen, and an instrument translatable through the displaced blood for performing any number of treatments upon the tissue surface within the field of view. The imaging hood may be formed into any number of configurations and the imaging assembly may also be utilized with any number of therapeutic tools which may be deployed through the deployment catheter.


More particularly in certain variations, the tissue visualization system may comprise components including the imaging hood, where the hood may further include a membrane having a main aperture and additional optional openings disposed over the distal end of the hood. An introducer sheath or the deployment catheter upon which the imaging hood is disposed may further comprise a steerable segment made of multiple adjacent links which are pivotably connected to one another and which may be articulated within a single plane or multiple planes. The deployment catheter itself may be comprised of a multiple lumen extrusion, such as a four-lumen catheter extrusion, which is reinforced with braided stainless steel fibers to provide structural support. The proximal end of the catheter may be coupled to a handle for manipulation and articulation of the system.


To provide visualization, an imaging element such as a fiberscope or electronic imager such as a solid state camera, e.g., CCD or CMOS, may be mounted, e.g., on a shape memory wire, and positioned within or along the hood interior. A fluid reservoir and/or pump (e.g., syringe, pressurized intravenous bag, etc.) may be fluidly coupled to the proximal end of the catheter to hold the translucent fluid such as saline or contrast medium as well as for providing the pressure to inject the fluid into the imaging hood.


In treating tissue regions which are directly visualized, as described above, one particular treatment involves deploying a stent within a vessel lumen or ostium while under direct visualization. An introducer sheath may be introduced into the patient's body utilizing conventional approaches such that the sheath is advanced intravascularly through the aorta where a guidewire may be advanced through the sheath and into, e.g., the right coronary artery. The treatment may be affected not only within and around the right coronary artery, but also the left coronary artery, left anterior descending artery, left circumflex artery, or any other vessel accessible by the assembly. As the guidewire is positioned within, e.g., the vessel lumen, the deployment catheter and hood may be deployed from the sheath and advanced along the guidewire until the circumference of the hood contacts against or in proximity to the ostium. Once the hood is in contact against the ostium, the clearing fluid may be introduced within the open area of the hood to purge the blood from the hood interior to provide a clear field through which an imaging element positioned within or along the hood may visualize through to view the underlying tissue surrounding the ostium and at least a portion of the vessel wall extending into the lumen.


A stent delivery assembly having an inflatable balloon in an un-inflated low-profile configuration and a stent crimped or otherwise positioned upon the balloon may be advanced through the catheter and distally out from the hood until the stent assembly is positioned in proximity or adjacent to, e.g., an ostial lesion, which is to be treated. The imaging element may be used to directly visualize at least partially into the lumen as the purged clearing fluid exits the hood and down through the lumen to provide an image of the lesion to be treated.


With the stent assembly desirably positioned and confirmed by direct visualization, the balloon may be inflated to expand the stent over the lesion, also while under visualization. In other variations, the balloon carrying the stent may be integrated with a visualization balloon positioned proximally of the stent assembly rather than a hood. The balloon may be subsequently deflated and then retracted back into the hood and the catheter leaving the deployed stent positioned desirably within the lumen. The imager may be used to visually confirm the deployment and positioning of the stent within the lumen.


In determining the size of the ostial lesion to be treated, the imaging capabilities of the hood may be utilized for optimally treating the patient by directly measuring not only the lesion but also the diameter of the vessel lumen for determining an appropriate stent to be deployed as the diameter of the vessel as well as the axial length of the lesion may affect the shape and size of the stent.


One example utilizes a measurement catheter having a number of gradations with known distances which may be advanced through the hood and into the lumen. With the purging fluid introduced through the hood and into the lumen, the markings on the catheter may be viewed and compared to the lesion directly to provide a more accurate measurement of the lesion length than provided by a fluoroscopic image alone. In other variations, expandable baskets or members each having a known expanded diameter may be positioned along a support catheter and advanced distally from the hood and into the lumen to measure a diameter of the vessel interior. The inner diameter of the vessel can thus be calculated by considering the diameter of the member which is blocked from entering the ostium. With the calculated length and diameter of the vessel and lesion to be treated, an appropriate stent may be selected for placement at the ostial lesion.


In yet another variation, a deployment catheter may utilize a hood having an angled interface which is angled relative to the catheter. The asymmetric slanted hood may be used to facilitate navigation within the aorta as the hood may be better able to engage against a tissue region or ostium and establish visualization without the need to steer and/or articulate the catheter shaft perpendicularly within the narrow aorta lumen.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a side view of one variation of a tissue imaging apparatus during deployment from a sheath or delivery catheter.



FIG. 1B shows the deployed tissue imaging apparatus of FIG. 1A having an optionally expandable hood or sheath attached to an imaging and/or diagnostic catheter.



FIG. 1C shows an end view of a deployed imaging apparatus.



FIGS. 2A and 2B show one example of a deployed tissue imager positioned against or adjacent to the tissue to be imaged and a flow of fluid, such as saline, displacing blood from within the expandable hood.



FIGS. 3A and 3B show examples of various visualization imagers which may be utilized within or along the imaging hood.



FIGS. 4A and 4B show perspective and end views, respectively, of an imaging hood having at least one layer of a transparent elastomeric membrane over the distal opening of the hood.



FIGS. 5A and 5B show perspective and end views, respectively, of an imaging hood which includes a membrane with an aperture defined therethrough and a plurality of additional openings defined over the membrane surrounding the aperture.



FIG. 6 illustrates an example of a system configured for visualization and stent delivery.



FIGS. 7A to 7C show partial cross-sectional views of deploying a stent intravascularly within a coronary artery while under direct visualization.



FIGS. 8A to 8C show partial cross-sectional detail views of a stent assembly introduced and deployed within a vessel while under direct visualization.



FIG. 9A shows a partial cross-sectional view of a measurement catheter deployed within a vessel for directly measuring a length of a lesion.



FIG. 9B shows a partial cross-sectional view of one or more measurement baskets or expandable members which may be utilized to measure an inner diameter of the vessel.



FIGS. 10A to 10C illustrate side views of measurement baskets or expandable members which may be deployed sequentially in determining the inner diameter of a vessel.



FIGS. 11A to 11E illustrate another variation where a stent may be positioned upon a balloon integrated with a visualization balloon positioned proximally of the stent for deployment within a vessel.



FIGS. 12A and 12B show a side view of a hood variation which utilizes an angled interface and the angled hood deployed within the body against an ostium.





DETAILED DESCRIPTION OF THE INVENTION

A tissue-imaging and manipulation apparatus described herein is able to provide real-time images in vivo of tissue regions within a body lumen such as a heart, which is filled with blood flowing dynamically therethrough and is also able to provide intravascular tools and instruments for performing various procedures upon the imaged tissue regions. Such an apparatus may be utilized for many procedures, e.g., facilitating transseptal access to the left atrium, cannulating the coronary sinus, diagnosis of valve regurgitation/stenosis, valvuloplasty, atrial appendage closure, arrhythmogenic focus ablation, among other procedures.


One variation of a tissue access and imaging apparatus is shown in the detail perspective views of FIGS. 1A to 1C. As shown in FIG. 1A, tissue imaging and manipulation assembly 10 may be delivered intravascularly through the patient's body in a low-profile configuration via a delivery catheter or sheath 14. In the case of treating tissue, it is generally desirable to enter or access the left atrium while minimizing trauma to the patient. To non-operatively effect such access, one conventional approach involves puncturing the intra-atrial septum from the right atrial chamber to the left atrial chamber in a procedure commonly called a transseptal procedure or septostomy. For procedures such as percutaneous valve repair and replacement, transseptal access to the left atrial chamber of the heart may allow for larger devices to be introduced into the venous system than can generally be introduced percutaneously into the arterial system.


When the imaging and manipulation assembly 10 is ready to be utilized for imaging tissue, imaging hood 12 may be advanced relative to catheter 14 and deployed from a distal opening of catheter 14, as shown by the arrow. Upon deployment, imaging hood 12 may be unconstrained to expand or open into a deployed imaging configuration, as shown in FIG. 1B. Imaging hood 12 may be fabricated from a variety of pliable or conformable biocompatible material including but not limited to, e.g., polymeric, plastic, or woven materials. One example of a woven material is Kevlar® (E. I. du Pont de Nemours, Wilmington, Del.), which is an aramid and which can be made into thin, e.g., less than 0.001 in., materials which maintain enough integrity for such applications described herein. Moreover, the imaging hood 12 may be fabricated from a translucent or opaque material and in a variety of different colors to optimize or attenuate any reflected lighting from surrounding fluids or structures, i.e., anatomical or mechanical structures or instruments. In either case, imaging hood 12 may be fabricated into a uniform structure or a scaffold-supported structure, in which case a scaffold made of a shape memory alloy, such as Nitinol, or a spring steel, or plastic, etc., may be fabricated and covered with the polymeric, plastic, or woven material. Hence, imaging hood 12 may comprise any of a wide variety of barriers or membrane structures, as may generally be used to localize displacement of blood or the like from a selected volume of a body lumen or heart chamber. In exemplary embodiments, a volume within an inner surface 13 of imaging hood 12 will be significantly less than a volume of the hood 12 between inner surface 13 and outer surface 11.


Imaging hood 12 may be attached at interface 24 to a deployment catheter 16 which may be translated independently of deployment catheter or sheath 14. Attachment of interface 24 may be accomplished through any number of conventional methods. Deployment catheter 16 may define a fluid delivery lumen 18 as well as an imaging lumen 20 within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, imaging hood 12 may expand into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field 26 is defined by imaging hood 12. The open area 26 is the area within which the tissue region of interest may be imaged. Imaging hood 12 may also define an atraumatic contact lip or edge 22 for placement or abutment against the tissue region of interest. Moreover, the diameter of imaging hood 12 at its maximum fully deployed diameter, e.g., at contact lip or edge 22, is typically greater relative to a diameter of the deployment catheter 16 (although a diameter of contact lip or edge 22 may be made to have a smaller or equal diameter of deployment catheter 16). For instance, the contact edge diameter may range anywhere from 1 to 5 times (or even greater, as practicable) a diameter of deployment catheter 16. FIG. 1C shows an end view of the imaging hood 12 in its deployed configuration. Also shown are the contact lip or edge 22 and fluid delivery lumen 18 and imaging lumen 20.


As seen in the example of FIGS. 2A and 2B, deployment catheter 16 may be manipulated to position deployed imaging hood 12 against or near the underlying tissue region of interest to be imaged, in this example a portion of annulus A of mitral valve MV within the left atrial chamber. As the surrounding blood 30 flows around imaging hood 12 and within open area 26 defined within imaging hood 12, as seen in FIG. 2A, the underlying annulus A is obstructed by the opaque blood 30 and is difficult to view through the imaging lumen 20. The translucent fluid 28, such as saline, may then be pumped through fluid delivery lumen 18, intermittently or continuously, until the blood 30 is at least partially, and preferably completely, displaced from within open area 26 by fluid 28, as shown in FIG. 2B.


Although contact edge 22 need not directly contact the underlying tissue, it is at least preferably brought into close proximity to the tissue such that the flow of clear fluid 28 from open area 26 may be maintained to inhibit significant backflow of blood 30 back into open area 26. Contact edge 22 may also be made of a soft elastomeric material such as certain soft grades of silicone or polyurethane, as typically known, to help contact edge 22 conform to an uneven or rough underlying anatomical tissue surface. Once the blood 30 has been displaced from imaging hood 12, an image may then be viewed of the underlying tissue through the clear fluid 30. This image may then be recorded or available for real-time viewing for performing a therapeutic procedure. The positive flow of fluid 28 may be maintained continuously to provide for clear viewing of the underlying tissue. Alternatively, the fluid 28 may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow 28 may cease and blood 30 may be allowed to seep or flow back into imaging hood 12. This process may be repeated a number of times at the same tissue region or at multiple tissue regions.



FIG. 3A shows a partial cross-sectional view of an example where one or more optical fiber bundles 32 may be positioned within the catheter and within imaging hood 12 to provide direct in-line imaging of the open area within hood 12. FIG. 3B shows another example where an imaging element 34 (e.g., CCD or CMOS electronic imager) may be placed along an interior surface of imaging hood 12 to provide imaging of the open area such that the imaging element 34 is off-axis relative to a longitudinal axis of the hood 12, as described in further detail below. The off-axis position of element 34 may provide for direct visualization and uninhibited access by instruments from the catheter to the underlying tissue during treatment.


In utilizing the imaging hood 12 in any one of the procedures described herein, the hood 12 may have an open field which is uncovered and clear to provide direct tissue contact between the hood interior and the underlying tissue to effect any number of treatments upon the tissue, as described above. Yet in additional variations, imaging hood 12 may utilize other configurations. An additional variation of the imaging hood 12 is shown in the perspective and end views, respectively, of FIGS. 4A and 4B, where imaging hood 12 includes at least one layer of a transparent elastomeric membrane 40 over the distal opening of hood 12. An aperture 42 having a diameter which is less than a diameter of the outer lip of imaging hood 12 may be defined over the center of membrane 40 where a longitudinal axis of the hood intersects the membrane such that the interior of hood 12 remains open and in fluid communication with the environment external to hood 12. Furthermore, aperture 42 may be sized, e.g., between 1 to 2 mm or more in diameter and membrane 40 can be made from any number of transparent elastomers such as silicone, polyurethane, latex, etc. such that contacted tissue may also be visualized through membrane 40 as well as through aperture 42.


Aperture 42 may function generally as a restricting passageway to reduce the rate of fluid out-flow from the hood 12 when the interior of the hood 12 is infused with the clear fluid through which underlying tissue regions may be visualized. Aside from restricting out-flow of clear fluid from within hood 12, aperture 42 may also restrict external surrounding fluids from entering hood 12 too rapidly. The reduction in the rate of fluid out-flow from the hood and blood in-flow into the hood may improve visualization conditions as hood 12 may be more readily filled with transparent fluid rather than being filled by opaque blood which may obstruct direct visualization by the visualization instruments.


Moreover, aperture 42 may be aligned with catheter 16 such that any instruments (e.g., piercing instruments, guidewires, tissue engagers, etc.) that are advanced into the hood interior may directly access the underlying tissue uninhibited or unrestricted for treatment through aperture 42. In other variations wherein aperture 42 may not be aligned with catheter 16, instruments passed through catheter 16 may still access the underlying tissue by simply piercing through membrane 40.


In an additional variation, FIGS. 5A and 5B show perspective and end views, respectively, of imaging hood 12 which includes membrane 40 with aperture 42 defined therethrough, as described above. This variation includes a plurality of additional openings 44 defined over membrane 40 surrounding aperture 42. Additional openings 44 may be uniformly sized, e.g., each less than 1 mm in diameter, to allow for the out-flow of the translucent fluid therethrough when in contact against the tissue surface. Moreover, although openings 44 are illustrated as uniform in size, the openings may be varied in size and their placement may also be non-uniform or random over membrane 40 rather than uniformly positioned about aperture 42 in FIG. 5B. Furthermore, there are eight openings 44 shown in the figures although fewer than eight or more than eight openings 44 may also be utilized over membrane 40.


Additional details of tissue imaging and manipulation systems and methods which may be utilized with apparatus and methods described herein are further described, for example, in U.S. patent application Ser. No. 11/259,498 filed Oct. 25, 2005 (U.S. Pat. Pub. No. 2006/0184048 A1, which is incorporated herein by reference in its entirety.


As the assembly allows for ablation of tissue directly visualized through hood 12, FIG. 6 illustrates an example of a system configured for visualization and stent delivery. As shown in visualization assembly 50, hood 12 and deployment catheter 16 are coupled to handle 52. Fluid reservoir 54, shown in this example as a saline-filled bag reservoir, may be attached through handle 52 to provide the clearing fluid and/or ablation medium. An optical imaging assembly 56 coupled to an imaging element 34 positioned within or adjacent to hood 12 may extend proximally through handle 52 and be coupled to imaging processor assembly 58 for processing the images detected within hood 12. The video processor assembly 58 may process the detected images within hood 12 for display upon video display 60. Handle 52 may further incorporate a delivery channel or port 62 through which a stent delivery assembly may be introduced for deployment of one or more stents into the patient's body through the deployment catheter 16 and hood 12.


One example for deploying a stent while under direct visualization is shown in the partial cross-sectional views of FIGS. 7A to 7C. Introducer sheath 14 may be introduced into the patient's body utilizing conventional approaches such that the sheath 14 is advanced intravascularly through the descending aorta DA and aortic arch AC and into the ascending aorta AA, where a guidewire 70 may be advanced through sheath 14 and into, e.g., the right coronary artery RCA. Treatment may be affected not only within and around the right coronary artery RCA, but also the left coronary artery LCA, left anterior descending artery, left circumflex artery, or any other vessel accessible by the assembly. As the guidewire 70 is positioned within, e.g., the lumen 72 of RCA as shown in FIG. 7A, deployment catheter 16 and hood 12 may be deployed from sheath 14 and advanced along guidewire 70, as shown in FIG. 7B, until the circumference of hood 12 contacts against or in proximity to ostium OS. Guidewire 70 may be omitted from the procedure, if so desired.


Once hood 12 is in contact against the ostium OS, the clearing fluid may be introduced within the open area of hood 12 to purge the blood from the hood interior to provide a clear field through which an imaging element positioned within or along hood 12 may visualize through to view the underlying tissue surrounding the ostium OS and at least a portion of the vessel wall extending into lumen 72.


As illustrated in the detail partial cross-sectional views of FIGS. 8A to 8C, with hood 12 positioned against or in proximity to ostium OS and the visual field cleared to provide visual imaging by imager 34, a stent delivery assembly 80 having an inflatable balloon 82 in an un-inflated low-profile configuration and a stent 84 crimped or otherwise positioned upon balloon 82 may be advanced through catheter 16 and distally out from hood 12 until stent assembly 80 is positioned in proximity or adjacent to, e.g., an ostial lesion 86, which is to be treated, as shown in FIG. 8A. Imager 34 may be used to directly visualize at least partially into lumen 72 as the purged clearing fluid exits hood 12 and down through lumen 72 to provide an image of the lesion 86 to be treated.


With stent assembly 80 desirably positioned and confirmed by direct visualization, balloon 82 may be inflated to expand stent 84 over lesion 86, as shown in FIG. 8B, also while under visualization. Balloon 82 may be subsequently deflated and then retracted back into hood 12 and catheter 16 leaving the deployed stent 84 positioned desirably within lumen 72. Imager 34 may be used to visually confirm the deployment and positioning of stent 84 within lumen 72, as shown in FIG. 8C.


In determining the size of the ostial lesion to be treated, the imaging capabilities of the hood 12 may be utilized for optimally treating the patient by directly measuring not only the lesion but also the diameter of the vessel lumen for determining an appropriate stent to be deployed as the diameter of the vessel as well as the axial length of the lesion may affect the shape and size of the stent.


One example is illustrated in the partial cross-sectional area of FIG. 9A, which shows hood 12 positioned against ostium OS with imager 34 visualizing the encompassed tissue and lesion 86. A measurement catheter 90 having a number of gradations 92 with known distances may be advanced through hood 12 and into lumen 72. With the purging fluid introduced through hood 12 and into lumen 72, the markings on catheter 90 may be viewed and compared to the lesion 86 directly to provide a more accurate measurement of the lesion length than provided by a fluoroscopic image alone.



FIG. 9B shows another example where one or more measurement baskets or expandable members 92, 94, 96, 98 (e.g., wire or mesh baskets, distensible membranes, etc.) may be utilized to measure an inner diameter of the vessel. Expandable baskets or members each having a known expanded diameter may be positioned along a support catheter 100 and advanced distally from hood 12 and into lumen 72 to measure a diameter of the vessel interior. The one or more members may be positioned along catheter 100 in increasing order of diameter size with colors, designs, markings, or other visual indications used to identify each particular member. Although four members 92, 94, 96, 98 are shown in the example, as few as one member or greater than four members may be utilized. Moreover, each subsequent member may be stepped in diameter size by a predetermined amount as desired. The members may be passed through the vessel ostium while under visualization in increasing order of diameter until the expanded basket is compressed or unable to cannulate the ostium OS. The inner diameter of the vessel can thus be calculated by considering the diameter of the member which is blocked from entering ostium OS. With the calculated length and diameter of the vessel and lesion to be treated, an appropriate stent 84 may be selected for placement at the ostial lesion 86.


In use, catheter 100 may be advanced through hood 12 with the one or more measurement baskets or expandable members 92, 94, 96, 98 configured in a delivery profile while constrained within sheath 102, as shown in the detail side view of FIG. 10A. Sheath 102 may be retracted, as indicated by the arrows, or catheter 100 may be advanced distally until each respective member is deployed and expanded, as shown in FIG. 10B, until all the members 92, 94, 96, 98 or an appropriate number of members have been deployed and expanded within the vessel lumen and/or proximate to the ostium OS, as shown in FIG. 10C.


In another variation, FIGS. 11A to 11E show cross-sectional views of a deployment catheter 16 utilizing an inflatable visualization balloon assembly 110 which remains enclosed rather than an open hood 12. The stent assembly 80 may be utilized with the visualization balloon 110 and positioned either through a lumen defined through the visualization balloon 110 or distally upon balloon 82, which in this example may be coupled as a separate balloon or integrated with visualization balloon 110 as a single balloon assembly, as shown in FIG. 11A. Balloon 82 in this variation may comprise a thin, tube-like deployment balloon with stent 84 crimped around it and with the relatively larger transparent visualization balloon 110 positioned proximally. Imager 34 may be positioned within balloon 110 for imaging through the balloons 110 and/or 82 for visualizing the ostium OS as well as the vessel walls.


With guidewire 70 advanced through the lumen 72 of, e.g., right coronary artery RCA, stent 84 and balloon 82 maybe inserted at least partially into the right coronary artery RCA. The proximal visualization balloon 110 may be inflated and pushed distally until the balloon surface is firmly in contact with the vessel ostium OS and free from blood between the balloon-tissue interface to visualize the ostium OS, as shown in FIG. 11B. The positioning of the stent 84 with respect to the ostial lesion 86 can thus be viewed with imaging element 34 inside the visualization balloon 110. Stent 84 can then be manipulated by pushing or pulling the balloon system against the ostial lesion 86. With the inflated visualization balloon 110 firmly pressing against the ostium OS, the operator may also be able to ensure that the stent 84 is not placed too proximally such that parts of the stent 84 is not protruding into the aortic lumen which can cause thrombus or other complications.


Upon visual confirmation that the stent 84 is positioned at its desired location and overlapping the ostial lesion 86, the deployment balloon 82 may be inflated until the stent 84 attains its stable configuration and is securely placed within the vessel, as shown in FIG. 11C, while the entire procedure is viewed under direct visualization with imaging element 34. Upon the successful placement of the stent 84 at the site of ostial lesion 86, one or both balloon 82 and/or visualization balloon 110 may be deflated and reduced to their original configuration and withdrawn, as shown in FIG. 11D. The assembly may then be withdrawn along with the guidewire 70 leaving behind the stent 84, as shown in FIG. 11E.


In yet another variation, FIG. 12A shows a side view of a deployment catheter 16 with hood 12 having an angled interface 120 which is angled relative to catheter 16. In this variation, an asymmetric, slanted hood 12 may be used to facilitate navigation within the aorta as the hood 12 may be better able to engage against a tissue region or ostium and establish visualization without the need to steer and/or articulate the catheter shaft perpendicularly within the narrow aorta lumen. As illustrated in FIG. 12B, angled interface 120 can be used to access the right coronary artery RCA without having to steer/articulate the deployment catheter 16 perpendicularly relative to ostium OS. A section of catheter 16 proximal to hood 12 can also optionally comprise a passive pre-shaped bend in place of an actively steerable section to assist the hood 12 in visualizing and accessing the coronary arteries.


The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.

Claims
  • 1. A tissue manipulation system, comprising: a reconfigurable hood structure with a distal end, the hood structure having a low profile delivery configuration and an expanded deployed configuration which defines an open area bounded at least in part by the structure and by a membrane extending across the hood structure distal end, the open area in fluid communication with an environment external to the hood structure, wherein the membrane includes an aperture with an aperture diameter smaller than an outer lip diameter of the hood structure in the expanded deployed configuration;a fluid lumen in communication with the open area such that introduction of a fluid through the lumen purges the open area of blood;an inflatable balloon member translatable through the aperture in the membrane and distal to the open area, wherein the balloon member has a low profile delivery configuration in which the balloon member is sized to pass through the aperture in the membrane, an inflated configuration in which the balloon member has an expanded diameter greater than the aperture diameter, and a deflated configuration in which the balloon member is sized for retraction through the aperture; andan expandable stent positioned upon the balloon member, wherein the stent has an unexpanded configuration when positioned on the balloon member in the low profile delivery configuration, the unexpanded configuration of the stent sized to pass through the aperture in the membrane and wherein the stent has an expanded configuration when positioned on the balloon member in the inflated configuration, the expanded configuration of the stent having an expanded diameter greater than the aperture diameter.
  • 2. The system of claim 1 further comprising an imaging element positioned within or along the structure such that the open area is visualized through the fluid by the element.
  • 3. The system of claim 1 wherein the inflatable balloon member is translatable through the hood structure when the balloon member is uninflated.
  • 4. The system of claim 1 further comprising a guidewire positioned through the hood structure.
  • 5. The system of claim 1 further comprising a measurement catheter defining one or more indications thereon and which is advanceable through the hood structure distal to the open area.
  • 6. The system of claim 1 further comprising one or more expandable measurement members positioned along a support member which is advanceable through the hood structure distal to the open area.
  • 7. The system of claim 6 wherein each of the one or more expandable measurement members includes two or more expandable measurement members, wherein each of the two or more expandable measurement members has a predetermined diameter whereby each subsequent expandable measurement member increases in diameter from a preceding member.
  • 8. The system of claim 6 wherein the one or more expandable measurement members are maintained with a sheath during advancement through the hood structure.
  • 9. A tissue manipulation system, comprising: a reconfigurable hood structure with a distal end, the structure having a low profile delivery configuration and an expanded deployed configuration which defines an open area bounded at least in part by the structure and by a membrane extending across the hood structure distal end, the open area in fluid communication with an environment external to the hood structure, wherein the membrane includes an aperture with an aperture diameter smaller than an outer lip diameter of the hood structure in the expanded deployed configuration;a catheter in communication with the open area such that introduction of a fluid through the catheter purges the open area of bodily fluid;an imaging element positioned on the hood structure such that the open area is visualized through the fluid by the imaging element;an inflatable balloon member translatable through the aperture in the membrane and distal to the open area, wherein the balloon member has a low profile delivery configuration in which the balloon member is sized to pass through the aperture in the membrane, an inflated configuration in which the balloon member has an expanded diameter greater than the aperture diameter, and a deflated configuration in which the balloon member is sized for retraction through the aperture; andan expandable stent positioned upon the balloon member, wherein the stent has an unexpanded configuration when positioned on the balloon member in the low profile delivery configuration, the unexpanded configuration of the stent sized to pass through the aperture in the membrane and wherein the stent has an expanded configuration when positioned on the balloon member in the inflated configuration, the expanded configuration of the stent having an expanded diameter greater than the aperture diameter.
  • 10. The system of claim 9 wherein the catheter includes a steerable segment proximal to the hood structure.
  • 11. The system of claim 10 wherein the steerable segment includes pivotally connected links.
  • 12. The system of claim 9 wherein the catheter includes a passively pre-shaped bend proximal to the hood structure.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/367,019, filed Feb. 6, 2009, which claims the benefit of priority to U.S. Prov. Pat. App. 61/026,795 filed Feb. 7, 2008, all of which are incorporated herein by reference in their entirety.

US Referenced Citations (534)
Number Name Date Kind
623022 Johnson Apr 1899 A
2305462 Wolf Dec 1942 A
2453862 Salisbury Nov 1948 A
3559651 David Feb 1971 A
3661148 Kolin May 1972 A
3874388 King et al. Apr 1975 A
4175545 Termanini Nov 1979 A
4326529 Doss et al. Apr 1982 A
4445892 Hussein et al. May 1984 A
4470407 Hussein Sep 1984 A
4517976 Murakoshi et al. May 1985 A
4569335 Tsuno Feb 1986 A
4576146 Kawazoe et al. Mar 1986 A
4615333 Taguchi Oct 1986 A
4619247 Inoue et al. Oct 1986 A
4676258 Inokuchi et al. Jun 1987 A
4681093 Ono et al. Jul 1987 A
4709698 Johnston et al. Dec 1987 A
4710192 Liotta et al. Dec 1987 A
4727418 Kato et al. Feb 1988 A
4784133 Mackin Nov 1988 A
4848323 Marijnissen et al. Jul 1989 A
4911148 Sosnowski et al. Mar 1990 A
4914521 Adair Apr 1990 A
4943290 Rexroth et al. Jul 1990 A
4950285 Wilk Aug 1990 A
4957484 Murtfeldt Sep 1990 A
4961738 Mackin Oct 1990 A
4976710 Mackin Dec 1990 A
4991578 Cohen Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
4998916 Hammerslag et al. Mar 1991 A
4998972 Chin et al. Mar 1991 A
5047028 Qian Sep 1991 A
5057106 Kasevich et al. Oct 1991 A
5090959 Samson et al. Feb 1992 A
5123428 Schwarz Jun 1992 A
RE34002 Adair Jul 1992 E
5156141 Krebs et al. Oct 1992 A
5171259 Inoue Dec 1992 A
5281238 Chin et al. Jan 1994 A
5282827 Kensey et al. Feb 1994 A
5306234 Johnson Apr 1994 A
5313943 Houser et al. May 1994 A
5330496 Alferness Jul 1994 A
5334159 Turkel Aug 1994 A
5334193 Nardella Aug 1994 A
5336252 Cohen Aug 1994 A
5339800 Wiita et al. Aug 1994 A
5348554 Imran et al. Sep 1994 A
5353792 Lubbers et al. Oct 1994 A
5370647 Graber et al. Dec 1994 A
5373840 Knighton Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5385148 Lesh et al. Jan 1995 A
5391182 Chin Feb 1995 A
5403326 Harrison et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5421338 Crowley et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5453785 Lenhardt et al. Sep 1995 A
5462521 Brucker et al. Oct 1995 A
5471515 Fossum et al. Nov 1995 A
5498230 Adair Mar 1996 A
5505730 Edwards Apr 1996 A
5515853 Smith et al. May 1996 A
5527338 Purdy Jun 1996 A
5549603 Feiring Aug 1996 A
5558619 Kami et al. Sep 1996 A
5571088 Lennox et al. Nov 1996 A
5575756 Karasawa et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5584872 LaFontaine et al. Dec 1996 A
5591119 Adair Jan 1997 A
5591195 Taheri Jan 1997 A
5593422 Muijs Van de Moer et al. Jan 1997 A
5593424 Northrup, III Jan 1997 A
5672153 Lax et al. Sep 1997 A
5676693 LaFontaine Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5695448 Kimura et al. Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5709224 Behl et al. Jan 1998 A
5713907 Hogendijk et al. Feb 1998 A
5713946 Ben-Haim Feb 1998 A
5716321 Kerin et al. Feb 1998 A
5722403 McGee et al. Mar 1998 A
5725523 Mueller Mar 1998 A
5746747 McKeating May 1998 A
5749846 Edwards et al. May 1998 A
5749890 Shaknovich May 1998 A
5754313 Pelchy et al. May 1998 A
5766137 Omata Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5792045 Adair Aug 1998 A
5797903 Swanson et al. Aug 1998 A
5823947 Yoon et al. Oct 1998 A
5827268 Laufer Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5842973 Bullard Dec 1998 A
5843118 Sepetka et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5860974 Abele Jan 1999 A
5860991 Klein et al. Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5873815 Kerin et al. Feb 1999 A
5879366 Shaw et al. Mar 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897487 Ouchi Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5902328 LaFontaine et al. May 1999 A
5904651 Swanson et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5925038 Panescu et al. Jul 1999 A
5928250 Koike et al. Jul 1999 A
5929901 Adair et al. Jul 1999 A
5941845 Tu et al. Aug 1999 A
5944690 Falwell et al. Aug 1999 A
5964755 Edwards Oct 1999 A
5968053 Revelas Oct 1999 A
5971983 Lesh Oct 1999 A
5986693 Adair et al. Nov 1999 A
5997571 Farr et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6024740 Lesh et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6036685 Mueller Mar 2000 A
6043839 Adair et al. Mar 2000 A
6047218 Whayne et al. Apr 2000 A
6063077 Schaer May 2000 A
6063081 Mulier et al. May 2000 A
6068653 LaFontaine May 2000 A
6071279 Whayne et al. Jun 2000 A
6071302 Sinofsky et al. Jun 2000 A
6081740 Gombrich et al. Jun 2000 A
6086528 Adair Jul 2000 A
6086534 Kesten Jul 2000 A
6099498 Addis Aug 2000 A
6099514 Sharkey et al. Aug 2000 A
6102905 Baxter et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6115626 Whayne et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6129724 Fleischman et al. Oct 2000 A
6139508 Simpson et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6156350 Constantz Dec 2000 A
6159203 Sinofsky Dec 2000 A
6161543 Cox et al. Dec 2000 A
6164283 Lesh Dec 2000 A
6167297 Benaron Dec 2000 A
6168591 Sinofsky Jan 2001 B1
6168594 LaFontaine et al. Jan 2001 B1
6174307 Daniel et al. Jan 2001 B1
6178346 Amundson et al. Jan 2001 B1
6190381 Olsen et al. Feb 2001 B1
6211904 Adair et al. Apr 2001 B1
6224553 Nevo May 2001 B1
6231561 Frazier et al. May 2001 B1
6235044 Root et al. May 2001 B1
6237605 Vaska et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6240312 Alfano et al. May 2001 B1
6254598 Edwards et al. Jul 2001 B1
6258083 Daniel et al. Jul 2001 B1
6263224 West Jul 2001 B1
6270492 Sinofsky Aug 2001 B1
6275255 Adair et al. Aug 2001 B1
6290689 Delaney et al. Sep 2001 B1
6306081 Ishikawa et al. Oct 2001 B1
6310642 Adair et al. Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6315777 Comben Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6322536 Rosengart et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6328727 Frazier et al. Dec 2001 B1
6358247 Altman et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6375654 McIntyre Apr 2002 B1
6379345 Constantz Apr 2002 B1
6385476 Osadchy et al. May 2002 B1
6387043 Yoon May 2002 B1
6387071 Constantz May 2002 B1
6394096 Constantz May 2002 B1
6396873 Goldstein et al. May 2002 B1
6398780 Farley et al. Jun 2002 B1
6401719 Farley et al. Jun 2002 B1
6409722 Hoey et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6419669 Frazier et al. Jul 2002 B1
6423051 Kaplan et al. Jul 2002 B1
6423055 Farr et al. Jul 2002 B1
6423058 Edwards et al. Jul 2002 B1
6428536 Panescu et al. Aug 2002 B2
6436118 Kayan Aug 2002 B1
6440061 Wenner et al. Aug 2002 B1
6440119 Nakada et al. Aug 2002 B1
6458151 Saltiel Oct 2002 B1
6464697 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475223 Werp et al. Nov 2002 B1
6478769 Parker Nov 2002 B1
6482162 Moore Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6488671 Constantz et al. Dec 2002 B1
6494902 Hoey et al. Dec 2002 B2
6497705 Comben Dec 2002 B2
6500174 Maguire et al. Dec 2002 B1
6502576 Lesh Jan 2003 B1
6514249 Maguire et al. Feb 2003 B1
6517533 Swaminathan Feb 2003 B1
6527979 Constantz et al. Mar 2003 B2
6532380 Close et al. Mar 2003 B1
6533767 Johansson et al. Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6540733 Constantz et al. Apr 2003 B2
6540744 Hassett et al. Apr 2003 B2
6544195 Wilson et al. Apr 2003 B2
6547780 Sinofsky Apr 2003 B1
6558375 Sinofsky et al. May 2003 B1
6558382 Jahns et al. May 2003 B2
6562020 Constantz et al. May 2003 B1
6572609 Farr et al. Jun 2003 B1
6579285 Sinofsky Jun 2003 B2
6585732 Mulier et al. Jul 2003 B2
6587709 Solf et al. Jul 2003 B2
6593884 Gilboa et al. Jul 2003 B1
6605055 Sinofsky et al. Aug 2003 B1
6613062 Leckrone et al. Sep 2003 B1
6622732 Constantz Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6626900 Sinofsky et al. Sep 2003 B1
6635070 Leeflang et al. Oct 2003 B2
6645202 Pless et al. Nov 2003 B1
6650923 Lesh et al. Nov 2003 B1
6658279 Swanson et al. Dec 2003 B2
6659940 Adler Dec 2003 B2
6673090 Root et al. Jan 2004 B2
6676656 Sinofsky Jan 2004 B2
6679836 Couvillon, Jr. et al. Jan 2004 B2
6682526 Jones et al. Jan 2004 B1
6689128 Sliwa et al. Feb 2004 B2
6692430 Adler Feb 2004 B2
6701581 Senovich et al. Mar 2004 B2
6701931 Sliwa et al. Mar 2004 B2
6702780 Gilboa et al. Mar 2004 B1
6704043 Goldstein et al. Mar 2004 B2
6706039 Mulier et al. Mar 2004 B2
6712798 Constantz Mar 2004 B2
6719747 Constantz et al. Apr 2004 B2
6719755 Sliwa et al. Apr 2004 B2
6730063 Delaney et al. May 2004 B2
6736810 Hoey et al. May 2004 B2
6751492 Ben-Haim Jun 2004 B2
6755790 Stewart et al. Jun 2004 B2
6755811 Constantz Jun 2004 B1
6764487 Mulier et al. Jul 2004 B2
6771996 Bowe et al. Aug 2004 B2
6773402 Govari et al. Aug 2004 B2
6780151 Grabover et al. Aug 2004 B2
6805128 Pless et al. Oct 2004 B1
6805129 Pless et al. Oct 2004 B1
6811562 Pless Nov 2004 B1
6833814 Gilboa et al. Dec 2004 B2
6840923 Lapcevic Jan 2005 B1
6840936 Sliwa et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6858005 Ohline et al. Feb 2005 B2
6858026 Sliwa et al. Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6866651 Constantz Mar 2005 B2
6887237 McGaffigan May 2005 B2
6892091 Ben-Haim et al. May 2005 B1
6896690 Lambrecht et al. May 2005 B1
6899672 Chin et al. May 2005 B2
6915154 Docherty et al. Jul 2005 B1
6916284 Moriyama Jul 2005 B2
6923805 LaFontaine et al. Aug 2005 B1
6929010 Vaska et al. Aug 2005 B2
6932809 Sinofsky Aug 2005 B2
6939348 Malecki et al. Sep 2005 B2
6942657 Sinofsky et al. Sep 2005 B2
6949095 Vaska et al. Sep 2005 B2
6953457 Farr et al. Oct 2005 B2
6955173 Lesh Oct 2005 B2
6962589 Mulier et al. Nov 2005 B2
6971394 Sliwa et al. Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6979290 Mourlas et al. Dec 2005 B2
6982740 Adair et al. Jan 2006 B2
6984232 Vanney et al. Jan 2006 B2
6994094 Schwartz Feb 2006 B2
7019610 Creighton et al. Mar 2006 B2
7025746 Tal Apr 2006 B2
7030904 Adair et al. Apr 2006 B2
7041098 Farley et al. May 2006 B2
7042487 Nakashima May 2006 B2
7044135 Lesh May 2006 B2
7052493 Vaska et al. May 2006 B2
7090683 Brock et al. Aug 2006 B2
7090688 Nishtala Aug 2006 B2
7118566 Jahns Oct 2006 B2
7156845 Mulier et al. Jan 2007 B2
7163534 Brucker et al. Jan 2007 B2
7166537 Jacobsen et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7186214 Ness Mar 2007 B2
7207984 Farr et al. Apr 2007 B2
7217268 Eggers et al. May 2007 B2
7242832 Carlin et al. Jul 2007 B2
7247155 Hoey et al. Jul 2007 B2
7261711 Mulier et al. Aug 2007 B2
7263397 Hauck et al. Aug 2007 B2
7276061 Schaer et al. Oct 2007 B2
7309328 Kaplan et al. Dec 2007 B2
7416552 Paul et al. Aug 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7527625 Knight et al. May 2009 B2
7534204 Starksen et al. May 2009 B2
7569052 Phan et al. Aug 2009 B2
7637934 Mangiardi et al. Dec 2009 B2
7651520 Fischell et al. Jan 2010 B2
7720528 Maschke May 2010 B2
7736347 Kaplan et al. Jun 2010 B2
7758499 Adler Jul 2010 B2
7860555 Saadat Dec 2010 B2
7860556 Saadat Dec 2010 B2
8078266 Saadat Dec 2011 B2
8131350 Saadat et al. Mar 2012 B2
8137333 Saadat et al. Mar 2012 B2
8690907 Janardhan Apr 2014 B1
8715314 Janardhan May 2014 B1
8784434 Rosenbluth Jul 2014 B2
8858609 Miller et al. Oct 2014 B2
9314324 Janardhan Apr 2016 B2
9592068 Janardhan Mar 2017 B2
20010020126 Swanson et al. Sep 2001 A1
20010039416 Moorman et al. Nov 2001 A1
20010047136 Domanik et al. Nov 2001 A1
20010047184 Connors Nov 2001 A1
20020004644 Koblish Jan 2002 A1
20020026145 Bagaoisan et al. Feb 2002 A1
20020054852 Cate May 2002 A1
20020065455 Ben-Haim et al. May 2002 A1
20020077564 Campbell Jun 2002 A1
20020087169 Brock et al. Jul 2002 A1
20020091304 Ogura et al. Jul 2002 A1
20020138088 Nash et al. Sep 2002 A1
20020147458 Hiblar Oct 2002 A1
20020165574 Ressemann Nov 2002 A1
20020165598 Wahr Nov 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20030009085 Arai et al. Jan 2003 A1
20030035156 Cooper Feb 2003 A1
20030036698 Kohler et al. Feb 2003 A1
20030069593 Tremulis et al. Apr 2003 A1
20030120142 Dubuc et al. Jun 2003 A1
20030130572 Phan et al. Jul 2003 A1
20030144657 Bowe et al. Jul 2003 A1
20030171741 Ziebol et al. Sep 2003 A1
20030181939 Bonutti Sep 2003 A1
20030208222 Zadno-Azizi Nov 2003 A1
20030212394 Pearson et al. Nov 2003 A1
20030220574 Markus et al. Nov 2003 A1
20030222325 Jacobsen et al. Dec 2003 A1
20040049211 Tremulis et al. Mar 2004 A1
20040054335 Lesh et al. Mar 2004 A1
20040054389 Osypka Mar 2004 A1
20040082833 Adler et al. Apr 2004 A1
20040093056 Johnson May 2004 A1
20040097788 Mourlas May 2004 A1
20040117032 Roth Jun 2004 A1
20040133113 Krishnan Jul 2004 A1
20040138707 Greenhalgh Jul 2004 A1
20040147806 Adler Jul 2004 A1
20040147852 Brister Jul 2004 A1
20040147911 Sinofsky Jul 2004 A1
20040147912 Sinofsky Jul 2004 A1
20040147913 Sinofsky Jul 2004 A1
20040158143 Flaherty et al. Aug 2004 A1
20040158289 Girouard et al. Aug 2004 A1
20040167503 Sinofsky Aug 2004 A1
20040181237 Forde et al. Sep 2004 A1
20040193243 Mangiardi Sep 2004 A1
20040199052 Banik et al. Oct 2004 A1
20040210239 Nash et al. Oct 2004 A1
20040215180 Starkebaum et al. Oct 2004 A1
20040220471 Schwartz Nov 2004 A1
20040230131 Kassab Nov 2004 A1
20040248837 Raz et al. Dec 2004 A1
20040249367 Saadat et al. Dec 2004 A1
20040254523 Fitzgerald et al. Dec 2004 A1
20040260182 Zuluaga et al. Dec 2004 A1
20050014995 Amundson et al. Jan 2005 A1
20050015048 Chiu et al. Jan 2005 A1
20050020914 Amundson et al. Jan 2005 A1
20050027163 Chin et al. Feb 2005 A1
20050038419 Arnold et al. Feb 2005 A9
20050059862 Phan Mar 2005 A1
20050059954 Constantz Mar 2005 A1
20050059965 Eberl et al. Mar 2005 A1
20050065504 Melsky et al. Mar 2005 A1
20050090818 Pike et al. Apr 2005 A1
20050096643 Brucker et al. May 2005 A1
20050101984 Chanduszko et al. May 2005 A1
20050107736 Landman et al. May 2005 A1
20050119523 Starksen Jun 2005 A1
20050124969 Fitzgerald et al. Jun 2005 A1
20050131401 Malecki et al. Jun 2005 A1
20050154252 Sharkey et al. Jul 2005 A1
20050159702 Sekiguchi et al. Jul 2005 A1
20050165279 Adler et al. Jul 2005 A1
20050165391 Maguire et al. Jul 2005 A1
20050165466 Morris et al. Jul 2005 A1
20050197530 Wallace Sep 2005 A1
20050197623 Leeflang et al. Sep 2005 A1
20050215895 Popp et al. Sep 2005 A1
20050222554 Wallace Oct 2005 A1
20050222557 Baxter et al. Oct 2005 A1
20050222558 Baxter et al. Oct 2005 A1
20050228417 Teitelbaum Oct 2005 A1
20050228452 Mourlas et al. Oct 2005 A1
20050234436 Baxter et al. Oct 2005 A1
20050234437 Baxter et al. Oct 2005 A1
20050267328 Blumzvig et al. Dec 2005 A1
20050278010 Richardson Dec 2005 A1
20060009715 Khairkhahan et al. Jan 2006 A1
20060009737 Whiting et al. Jan 2006 A1
20060015096 Hauck et al. Jan 2006 A1
20060022234 Adair et al. Feb 2006 A1
20060025651 Adler et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060069303 Couvillon Mar 2006 A1
20060074398 Whiting et al. Apr 2006 A1
20060084839 Mourlas et al. Apr 2006 A1
20060084945 Moll et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060111614 Saadat et al. May 2006 A1
20060122587 Sharareh Jun 2006 A1
20060146172 Jacobsen et al. Jul 2006 A1
20060149331 Mann et al. Jul 2006 A1
20060155242 Constantz Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060167439 Kalser et al. Jul 2006 A1
20060183992 Kawashima Aug 2006 A1
20060217755 Eversull et al. Sep 2006 A1
20060224167 Weisenburgh et al. Oct 2006 A1
20060253113 Arnold et al. Nov 2006 A1
20060258909 Saadat et al. Nov 2006 A1
20060271032 Chin et al. Nov 2006 A1
20070005019 Okishige Jan 2007 A1
20070015964 Eversull et al. Jan 2007 A1
20070016130 Leeflang Jan 2007 A1
20070043338 Moll et al. Feb 2007 A1
20070043413 Eversull et al. Feb 2007 A1
20070049923 Jahns Mar 2007 A1
20070055142 Webler Mar 2007 A1
20070078451 Arnold et al. Apr 2007 A1
20070083187 Eversull et al. Apr 2007 A1
20070083217 Eversull et al. Apr 2007 A1
20070093808 Mulier et al. Apr 2007 A1
20070100324 Tempel et al. May 2007 A1
20070106146 Altmann et al. May 2007 A1
20070106214 Gray et al. May 2007 A1
20070106287 O'Sullivan May 2007 A1
20070123776 Aharoni May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070167801 Webler et al. Jul 2007 A1
20070225790 Fischell et al. Sep 2007 A1
20070265609 Thapliyal et al. Nov 2007 A1
20070265610 Thapliyal et al. Nov 2007 A1
20070270686 Ritter et al. Nov 2007 A1
20070287886 Saadat Dec 2007 A1
20070293724 Saadat Dec 2007 A1
20080009747 Saadat et al. Jan 2008 A1
20080009859 Auth et al. Jan 2008 A1
20080015563 Hoey et al. Jan 2008 A1
20080015569 Saadat et al. Jan 2008 A1
20080027464 Moll et al. Jan 2008 A1
20080033241 Peh et al. Feb 2008 A1
20080057106 Erickson et al. Mar 2008 A1
20080058590 Saadat et al. Mar 2008 A1
20080058650 Saadat et al. Mar 2008 A1
20080058836 Moll et al. Mar 2008 A1
20080097476 Peh et al. Apr 2008 A1
20080183081 Lys et al. Jul 2008 A1
20080188759 Saadat et al. Aug 2008 A1
20080214889 Saadat et al. Sep 2008 A1
20080228032 Starksen et al. Sep 2008 A1
20080275300 Rothe et al. Nov 2008 A1
20080281293 Peh et al. Nov 2008 A1
20080287790 Li Nov 2008 A1
20080287805 Li Nov 2008 A1
20090030276 Saadat et al. Jan 2009 A1
20090030412 Willis et al. Jan 2009 A1
20090054803 Saadat et al. Feb 2009 A1
20090062790 Malchano et al. Mar 2009 A1
20090076489 Welches et al. Mar 2009 A1
20090076498 Saadat et al. Mar 2009 A1
20090082623 Rothe et al. Mar 2009 A1
20090112251 Qian Apr 2009 A1
20090125022 Saadat et al. May 2009 A1
20090143640 Saadat et al. Jun 2009 A1
20090187074 Saadat et al. Jul 2009 A1
20090198269 Hannes Aug 2009 A1
20090203962 Miller et al. Aug 2009 A1
20090221871 Peh et al. Sep 2009 A1
20090227999 Willis et al. Sep 2009 A1
20090264727 Markowitz et al. Oct 2009 A1
20090267773 Markowitz et al. Oct 2009 A1
20090275799 Saadat et al. Nov 2009 A1
20090299363 Saadat et al. Dec 2009 A1
20090306702 Miloslavski Dec 2009 A1
20090326572 Peh et al. Dec 2009 A1
20100004506 Saadat Jan 2010 A1
20100004633 Rothe et al. Jan 2010 A1
20100004661 Verin et al. Jan 2010 A1
20100010311 Miller et al. Jan 2010 A1
20100094081 Rothe et al. Apr 2010 A1
20100130836 Malchano et al. May 2010 A1
20110060227 Saadat Mar 2011 A1
20110060298 Saadat Mar 2011 A1
20110144576 Rothe et al. Jun 2011 A1
20120016221 Saadat et al. Jan 2012 A1
20120059366 Drews et al. Mar 2012 A1
20150374483 Janardhan Dec 2015 A1
Foreign Referenced Citations (39)
Number Date Country
10028155 Dec 2000 DE
0283661 Sep 1988 EP
0301288 Feb 1989 EP
S5993413 May 1984 JP
S59181315 Oct 1984 JP
H01221133 Sep 1989 JP
H03284265 Dec 1991 JP
H05103746 Apr 1993 JP
H0951897 Feb 1997 JP
H11299725 Nov 1999 JP
2001258822 Sep 2001 JP
WO-9221292 Dec 1992 WO
WO-9407413 Apr 1994 WO
WO-9503843 Feb 1995 WO
WO-9818388 May 1998 WO
WO-03039350 May 2003 WO
WO-03053491 Jul 2003 WO
WO-03101287 Dec 2003 WO
WO-2004043272 May 2004 WO
WO-2004080508 Sep 2004 WO
WO-2005070330 Aug 2005 WO
WO-2005077435 Aug 2005 WO
WO-2005081202 Sep 2005 WO
WO-2006017517 Feb 2006 WO
WO-2006024015 Mar 2006 WO
WO-2006083794 Aug 2006 WO
WO-2006091597 Aug 2006 WO
WO-2006126979 Nov 2006 WO
WO-2007067323 Jun 2007 WO
WO-2007079268 Jul 2007 WO
WO-2007133845 Nov 2007 WO
WO-2007134258 Nov 2007 WO
WO-2008015625 Feb 2008 WO
WO-2008021994 Feb 2008 WO
WO-2008021997 Feb 2008 WO
WO-2008021998 Feb 2008 WO
WO-2008024261 Feb 2008 WO
WO-2008079828 Jul 2008 WO
WO-2009112262 Sep 2009 WO
Non-Patent Literature Citations (75)
Entry
Baker B.M., et al., “Nonpharmacologic Approaches to the Treatment of Atrial Fibrillation and Atrial Flutter,” Journal of Cardiovascular Electrophysiology, 1995, vol. 6 (10 Pt 2), pp. 972-978.
Bhakta D., et al., “Principles of Electroanatomic Mapping,” Indian Pacing and Electrophysiology Journal, 2008, vol. 8 (1), pp. 32-50.
Bidoggia H., et al., “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocoardiogram in the Localization of the Fossa Ovalis,” Cathet Cardiovasc Diagn, 1991, vol. 24 (3), pp. 221-225, PMID: 1764747 [online], [retrieved Feb. 15, 2010]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/sites/entrez>.
Bredikis J.J., et al., “Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation,” Pacing and Clinical Electrophysiology, 1990, vol. 13 (Part 2), pp. 1980-1984.
Communication from the Examining Division for Application No. EP06734083.6 dated Nov. 12, 2010, 3 pages.
Communication from the Examining Division for Application No. EP06734083.6 dated Oct. 23, 2009, 1 page.
Communication from the Examining Division for Application No. EP08746822.9 dated Jul. 13, 2010, 1 page.
U.S. Appl. No. 61/286,283, filed Dec. 14, 2009.
U.S. Appl. No. 61/297,462, filed Jan. 22, 2010.
Cox J.L., “Cardiac Surgery for Arrhythmias,” Journal of Cardiovascular Electrophysiology, 2004, vol. 15, pp. 250-262.
Cox J.L., et al., “Five-Year Experience With the Maze Procedure for Atrial Fibrillation,” The Annals of Thoracic Surgery, 1993, vol. 56, pp. 814-824.
Cox J.L., et al., “Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1995, vol. 110, pp. 473-484.
Cox J.L., “The Status of Surgery for Cardiac Arrhythmias,” Circulation, 1985, vol. 71, pp. 413-417.
Cox J.L., “The Surgical Treatment of Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1991, vol. 101, pp. 584-592.
Elvan A., et al., “Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dogs,” Circulation, vol. 91, 1995, pp. 2235-2244 [online], [retrieved Feb. 4, 2013]. Retrieved from the Internet: <URL: http://circ.ahajournals.org/cgi/content/full/91/8/2235>.
Elvan A., et al., “Radiofrequency Catheter Ablation (RFCA) of the Atria Effectively Abolishes Pacing Induced Chronic Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 856.
Elvan, et al., “Replication of the ‘Maze’ Procedure by Radiofrequency Catheter Ablation Reduces the Ability to Induce Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
European Search Report for Application No. EP07799466.3 dated Nov. 18, 2010, 9 pages.
European Search Report for Application No. EP08746822.9 dated Mar. 29, 2010, 7 Pages.
Examination Communication for Application No. EP06734083.6 dated May 18, 2010, 3 Pages.
Extended European Search Report for Application No. EP06734083.6 dated Jul. 1, 2009, 6 pages.
Fieguth H.G., et al., “Inhibition of Atrial Fibrillation by Pulmonary Vein Isolation and Auricular Resection—Experimental Study in a Sheep Model,” The European Journal of Cardio-Thoracic Surgery, 1997, vol. 11, pp. 714-721.
Final Office Action dated Mar. 1, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated Jun. 2, 2011 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated May 12, 2011 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Final Office Action dated Sep. 16, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Hoey M.F., et al., “Intramural Ablation Using Radiofrequency Energy Via Screw-Tip Catheter and Saline Electrode,” Pacing and Clinical Electrophysiology, 1995, vol. 18, Part II, 487.
Huang, “Increase in the Lesion Size and Decrease in the Impedance Rise with a Saline Infusion Electrode Catheter for Radiofrequency,” Circulation, 1989, vol. 80 (4), II-324.
Moser K.M ., et al., “Angioscopic Visualization of Pulmonary Emboli,” Chest, 1980, vol. 77 (2), pp. 198-201.
Nakamura F., et al., “Percutaneous Intracardiac Surgery With Cardioscopic Guidance,” SPIE, 1992, vol. 1642, pp. 214-216.
Non-Final Office Action dated Jun. 7, 2011 for U.S. Appl. No. 12/323,281, filed Nov. 25, 2008.
Non-Final Office Action dated Jun. 8, 2009 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,950, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,995, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/962,029, filed Dec. 20, 2007.
Non-Final Office Action dated Jun. 10, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Non-Final Office Action dated Apr. 11, 2011 for U.S. Appl. No. 11/763,399, filed Jun. 14, 2007.
Non-Final Office Action dated Mar. 11, 2011 for U.S. Appl. No. 11/848,202, filed Aug. 30, 2007.
Non-Final Office Action dated May 11, 2011 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Apr. 12, 2011 for U.S. Appl. No. 12/499,011, filed Jul. 7, 2009.
Non-Final Office Action dated Jan. 14, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Dec. 16, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,198, filed Nov. 16, 2010.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,246, filed Nov. 16, 2006.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/775,819, filed Jul. 10, 2007.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/877,386, filed Oct. 23, 2007.
Non-Final Office Action dated Jul. 21, 2010 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Non-Final Office Action dated May 23, 2011 for U.S. Appl. No. 11/775,837, filed Jul. 10, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 11/848,429, filed Aug. 31, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 12/464,800, filed May 12, 2009.
Non-Final Office Action dated Apr. 25, 2011 for U.S. Appl. No. 11/959,158, filed Dec. 18, 2007.
Non-Final Office Action dated Feb. 25, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Non-Final Office Action dated Feb. 25, 2011 for U.S. Appl. No. 11/848,207, filed Aug. 30, 2007.
Non-Final Office Action dated Apr. 26, 2011 for U.S. Appl. No. 11/848,532, filed Aug. 31, 2007.
Non-Final Office Action dated Apr. 27, 2011 for U.S. Appl. No. 11/828,281, filed Jul. 25, 2007.
Non-Final Office Action dated Aug. 27, 2010 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Non-Final Office Action dated Dec. 27, 2010 for U.S. Appl. No. 12/026,455, filed Feb. 5, 2008.
Notice of Allowance dated Feb. 3, 2011 for U.S. Appl. No. 11/560,732, filed Nov. 16, 2006.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/560,732, filed Mar. 16, 2007.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Office Action dated Feb. 15, 2011 for Japanese Application No. 2007-554156 filed Jan. 30, 2006.
Office Action dated Apr. 27, 2011 for Japanese Application No. 2009-500630 filed Mar. 16, 2007.
Pappone C., et al., “Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia,” Circulation, 2000, vol. 102, pp. 2619-2628.
Sethi K.K., et al., “Transseptal catheterization for the electrophysiologist: modification with a ‘view’” Journal of Interventional Cardiac Electrophysiology, 2001, vol. 5 (1), pp. 97-99.
Supplemental European Search Report for Application No. EP07758716 dated Feb. 28, 2011, 8 Pages.
Supplementary European search report for Application No. EP07812146.4 dated Nov. 18, 2010, 8 Pages.
Supplementary European Search Report for Application No. EP07841754, dated Jun. 30, 2010, 6 pages.
Thiagalingam A., et al., “Cooled Needle Catheter Ablation Creates Deeper and Wider Lesions than Irrigated Tip Catheter Ablation,” Journal of Cardiovascular Electrophysiology, 2005, vol. 16 (5), pp. 1-8.
Uchida Y., “Developmental History of Cardioscopes”, in: Coronary Angioscopy, Chapter 19, Futura Publishing Company, Inc., 2001, pp. 187-197.
Willkampf F.H., et al., “Radiofrequency Ablation with a Cooled Porous Electrode Catheter,” JACC, Abstract,1988, vol. 11 (2), pp. 17A.
Avitall B., et al., “Right-Sided Driven Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, et al. “A Catheter System to Ablate Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, “Vagally Mediated Atrial Fibrillation in a Dog Model can be Ablated by Placing Linear Radiofrequency Lesions at the Junction of the Right Atrial Appendage and the Superior Vena Cava,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 857.
Related Publications (1)
Number Date Country
20150025614 A1 Jan 2015 US
Provisional Applications (1)
Number Date Country
61026795 Feb 2008 US
Continuations (1)
Number Date Country
Parent 12367019 Feb 2009 US
Child 14490107 US